How Does DM365 MainEDC Claim to Speed Up Clinical Trials and Reduce Costs?

DM365's MainEDC platform claims to shorten study startup to days rather than weeks and to cut platform and monitoring spend by up to 80% and 75% respectively. These are vendor claims published on datamanagement365.com; the site presents them as portfolio outcomes across 148 pharma, biotech, and CRO clients rather than as guarantees for every study. The claims are most relevant if you are launching a trial under FDA, EMA, or other regulatory submission requirements and want a pre-validated EDC/ePRO stack with templates instead of building one from scratch.

The speed claims and what backs them

The site makes three distinct speed assertions:

• Deployment in days: "Deploy studies in days" with a 9.2-day median FPI (first patient in) after project start.
• FPI in 2 days is cited as an achievement within its portfolio of 100+ sponsors.
• Against industry baseline: the site states the average industry project start takes 12.7 weeks and claims MainEDC can compress that to as fast as 5 days.

The mechanism the site attributes this to is ready-to-use tools, templates, and data management/Data Science best practices, plus a "prompt and easy eCRF building" process using an advanced Visual Edit-checks Builder. In practical terms, the claim rests on reusing pre-built CRF structures and edit-check logic rather than designing each study from a blank slate — the same lever any experienced DM team uses, packaged as a product.

Protocol amendments

The site specifically claims "quick deployment and adjustments to protocol amendments." This matters because amendments are a common source of mid-study delay; the claim implies the visual builder lets you modify forms and checks without a full rebuild. The site does not publish amendment turnaround metrics, so treat this as a qualitative claim.

The cost claims

The savings are framed as comparisons against conventional platform and monitoring costs, not as absolute prices. The site links to a Pricing page but the excerpt does not disclose actual rates, so you cannot verify the 80%/75% figures without a quote. The "pay as you go" language applies to the ePRO module in the text shown.

What the platform includes

The site lists these modules under Solutions & Services:

• MainEDC Platform (core EDC)
• MainEDC ePRO — patient-reported outcomes, with investigator access via a dedicated subdomain (www.yourcompany.investigator.site)
• MainEDC Storage
• MainPACS
• MainEDC RBM (risk-based monitoring)
• MainEDC Register

It also advertises AI-based automated medical coding as "the first market solution based on AI for automated medical coding," and compliance with GCP E6 R2, GAMP 5, 21 CFR Part 11, GDPR, and HIPAA, with private cloud hosting.

Who the claims are pitched at

The site segments its messaging, which tells you where the speed and cost arguments are meant to land:

• Big Pharma: portfolio scale (70,000+ subject trials) and AI coding.
• CROs: an industry solution that produces a document package for registration with any regulatory authority (FDA, EMA, etc.), i.e., savings through reuse across many trials.
• Biotech: teams running trials for the first time or infrequently, where DM365 positions itself as an extension of your team.

There is also a "Transfer of Competence" service — shared work on your project to transfer data management, data science, or drug management expertise — and services covering technology transfer, IT security and infrastructure, quality assurance, validation, and mentoring.

How to test the claims before committing

1. Request the free trial (the site offers "Get Free Trial") and build one representative CRF with edit checks in the Visual Edit-checks Builder. Time it against your own historical build time.
2. Ask for the 9.2-day median FPI evidence — specifically, how many studies it covers and whether they resemble your protocol complexity.
3. Get a written quote covering EDC, ePRO, and monitoring separately, then compare against your current vendor on the same scope; the 80%/75% figures are only meaningful against a defined baseline.
4. Confirm the validation package for your target regulator and ask how audit/inspection support is delivered — the site says it helps users answer auditor and inspector questions about the platform.
5. Schedule a demo through the site's contact path to see amendment handling live, since that is the claim with the least published detail.

The main caveat: every figure above is a vendor statement from the site's own marketing pages. The speed and savings are plausible for teams without existing templates, but they depend on protocol complexity and on how much of your current cost base is actually platform and monitoring spend.